-
Rofecoxib is a COX-2-selective
nonsteroidal anti-inflammatory drug (NSAID). It was
marketed by
Merck & Co. to
treat osteoarthritis,
rheumatoid arthritis...
-
reduces the risk of
peptic ulceration and is the main
feature of celecoxib,
rofecoxib, and
other members of this drug class.
After several COX-2–inhibiting...
-
heart attack. As a result,
certain COX-2
selective inhibitors—such as
rofecoxib—are no
longer used due to the high risk of
undiagnosed vascular disease...
-
complicated upper gastrointestinal events are
similar between two groups. Like
rofecoxib's VIGOR trial, the
MEDAL Program was also criticized, this time due to...
-
advice to
physicians regarding celecoxib's safety. The COX-2
inhibitor rofecoxib (Vioxx) was
removed from the
market in 2004 due to its risk. Like all...
- (traditional
NSAIDs block both
versions in general).
These drugs (such as
rofecoxib, celecoxib, and etoricoxib) are
equally effective analgesics when compared...
- of
increased risks of
heart attacks with the
selective COX-2
inhibitor rofecoxib in 2004,
attention has
focused on all the
other members of the nonsteroidal...
-
became the building-block for
synthesis of COX-2 inhibitors.
Celecoxib and
rofecoxib, the
first COX-2
inhibitors to
reach market, were
based on DuP-697. It...
- A.; et al. (2000). "Comparison of
upper gastrointestinal toxicity of
rofecoxib and
naproxen in
patients with
rheumatoid arthritis". New
England Journal...
- double-blind,
clinical trial comparing the
efficacy of nimesulide,
celecoxib and
rofecoxib in
osteoarthritis of the knee". Drugs. 63 (Suppl 1): 37–46. doi:10...
